Awaiting product image

Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016

$2,500.00 – $5,000.00

SKU: KLI4859780 Category: Pages: 220

Description

What Will the Pharma Industry Look Like in 5 Years?

There are an estimated 724 projects in development from the top 50 pharmaceutical companies.  Together, they have the potential to add billions in value to the current pharmaceutical market in the next five years. What types of drugs are companies developing and what will be the impact of these products on the marketplace and key competitors?   In this report, Kalorama Information has analyzed the late-stage R&D pipeline of the 50 top companies in pharmaceuticals — the companies that produce the lion’s share of industry revenues.

Coverage of the 50 Leading Companies
 This report takes a look at the pipeline of the following companies.  The top companies include pharmaceutical companies that are considered to be the top 50 companies worldwide in terms of generated revenues, these include:

  • Abbott Laboratories
  • Actelion
  • Allergan
  • Amgen
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Biogen IDEC
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corp.
  • CSL
  • Daiichi Sankyo
  • Dainippon Sumitomo
  • Eisai
  • Eli Lilly & Co.
  • Forest
  • Gilead Sciences
  • GlaxoSmithKline
  • Grifols SA
  • Hospira
  • Johnson & Johnson
  • Kyowa Kirin
  • Lundbeck
  • Menarini
  • Merck
  • Merck KGaA
  • Mitsubishi Tanabe Pharma
  • Mylan
  • Novartis
  • Novo Nordisk
  • Ono Pharmaceutical Co.
  • Otsuka Pharmaceutical
  • Pfizer
  • Purdue Pharma
  • Reckitt Benckiser
  • Roche
  • Sanofi
  • Santen Pharmaceuticals
  • Servier
  • Shionogi
  • Shire
  • Taisho Pharmacueitcal
  • Takeda
  • TEVA
  • UCB
  • Valeant Pharmaceuticals
  • Warner Chilcott
  • Watson
While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products.  The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.
Pipeline Analysis, Key Trends, Market Forecasts
This Kalorama Information market research report captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines and OTC products) and providing estimates and forecasts of the world biopharma market.

As part of its coverage, the report provides the following:

  • Company Analysis
  • Pipeline Snapshot: Top 20 Companies
  • Market Trends and Value
  • Evaluating Changes in 2011 Market Value
  • The Traditional Pharmaceutical Market
  • Biotechnology Market Facts and Forecast

For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical and biopharmaceutical products; consumer pharmaceuticals and products; diagnostics; devices; chemicals; agriculture; and animal health. These are areas where many of these companies also compete with significant market shares.

The industry has struggled in recent years but many observers see biopharmaceutical as the key to continued success for market leaders.  Biopharmaceuticals are defined as any substance produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms for the treatment or management of diseases or injuries. Biopharmaceuticals are created through fermentation, recombinant DNA technology, and other bioprocesses. The complex nature of biopharmaceuticals and the growing interest in development of these products has resulted in a flood of new issues affecting the already complicated healthcare market. There are a number of issues and trends which are experienced by the healthcare industry as a whole and others which are unique to biopharmaceuticals, their development and commercialization.

Issues and Trends discussed in this report include:

  • Biotechnology Drug Development
  • Orphan Drugs
  • Fast Track Drug Status
  • Other Accelerated Methods for Drug Approval
  • Pharmaceutical Regulatory Exclusivity
  • Biosimilar Development
  • Aging Populations
  • Mergers, Acquisitions, and Collaborations
  • Contributors to R&D Success
  • R&D Spending Trends
  • The Role of Contract Research Organizations
  • Sustainability in a Changing Pharmaceutical Industry

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • IntroductionScope and Methodology
  • Potential Market Opportunity
  • Issues and Trends Affecting Market
  • Leading Companies

CHAPTER TWO: INTRODUCTION

  • Global Pharmaceutical MarketPharmaceutical Research & Development Overview
  • Expanded Options in Treating Diseases

CHAPTER THREE: ISSUES AND TRENDS

  • Biotechnology Drug DevelopmentOrphan Drugs
  • Fast Track Drug Status
  • Other Accelerated Methods for Drug Approval
  • Pharmaceutical Regulatory Exclusivity
  • Pediatric Extensions
  • Biopharmaceutical Industry—Biosimilar (Biogeneric) Development and Exclusivity Legislation
  • Aging Population
  • Mergers, Acquisitions, and Collaborations
  • Contributors To R&D Success
  • R&D Spending
  • The Role of Contract Research Organization
  • Sustainability in a Changing Pharmaceutical Industry

CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS

  • IntroductionPfizer, Inc.
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Merck & Co., Inc.
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Novartis
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Sanofi
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Roche Ltd.
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • GlaxoSmithKline plc
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • AstraZeneca plc
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Johnson & Johnson
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Eli Lilly & Company
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Abbott Laboratories
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Bristol-Myers Squibb Company
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Takeda Pharmaceutical Co., Ltd.
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • TEVA Pharmaceutical Industries, Ltd.
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Amgen, Inc.
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Boehringer Ingelheim GmbH
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Bayer AG
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Novo Nordis
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Astellas
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Daiichi Sankyo
    • Overview
    • Financial Performance and Investmen
    • Late Stage Pipeline
  • Otsuka
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline

CHAPTER FIVE: COMPANIES OF INTEREST

  • IntroductionMerck KGaA
    • Late Stage Pipeline
  • Gilead Sciences
    • Late Stage Pipeline
  • Eisai
    • Late Stage Pipeline
  • Mylan
    • Pipeline
  • Baxter International
    • Pipeline
  • Servier, Les Laboratories
    • Pipeline
  • Celgene Corporation
    • Late Stage Pipeline
  • Mitsubishi Tanabe
    • Late Stage Pipeline
  • Allergan
    • Late Stage Pipeline
  • Forest Laboratories
    • Late Stage Pipeline
  • CSL Limited
    • Late Stage Pipeline
  • UCB SA
    • Late Stage Pipeline
  • Dainippon Sumitomo Pharma, Co., Ltd.
    • Late Stage Pipeline
  • Shire
    • Late Stage Pipeline
  • Biogen Idec
    • Late Stage Pipeline
  • Watson
    • Pipeline
  • Hospira
    • Late Stage Pipeline
  • Lundbeck A/S
    • Late Stage Pipeline
  • Kyowa Kirin
    • Late Stage Pipeline
  • Warner Chilcott plc
    • Late Stage Pipeline
  • Menarini Group
    • Late Stage Pipeline
  • Valeant Pharmaceuticals
    • Late Stage Pipeline
  • Purdue Pharma
    • Late Stage Pipeline
  • Grifols SA
    • Late Stage Pipeline
  • Shionogi & Co., Ltd.
    • Late Stage Pipeline
  • Actelion
    • Late Stage Pipeline
  • Ono Pharmaceutical Co.
    • Late Stage Pipeline
  • Santen Pharmaceutical Co.
    • Late Stage Pipeline
  • Reckitt Benckiser
    • Late Stage Pipeline
  • Taisho Pharmaceutical Co.
    • Late Stage Pipeline

CHAPTER SIX: MARKET FORECAST

  • OverviewCompany Analysis
  • Pipeline Snapshot: Top 20 Companies
  • Market Trends and Value
  • Evaluating Changes in 2011 Market Value
  • Market Forecast
  • The Traditional Biotechnology Market
  • Biotechnology Market Facts and Forecast

APPENDIX: LIST OF COMPANIES

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016—based on late stage development projects evaluatedFigure 1-1: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016—Potential Impact from Late-Stage Development

CHAPTER TWO: INTRODUCTION

  • Table 2-1: Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000 and 2009Figure 2-1: Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000, and 2009
  • Table 2-2: Phases of Clinical Drug Development
  • Table 2-3: Components of a Clinical Trial
  • Figure 2-2: Biotechnology Approvals by Year Range (FDA)

CHAPTER THREE: ISSUES AND TRENDS

  • Table 3-1: International Population Trend Age 65+Table 3-2: United States Population Trend Age 65+
  • Table 3-3: Recent Pharmaceutical Business Mergers and Acquisitions
  • Table 3-4: Pharmaceutical/Biopharmaceutical R&D Statistics
  • Table 3-5: Total Industry R&D Spending 2004-2010

CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS

  • Table 4-1: Top Biopharmaceutical Companies, 1-20 by 2011 SalesTable 4-2: Pfizer’s Total Company Revenue and R&D Spending 2007-2011
  • Figure 4-1: Pfizer’s Total Company Revenue and R&D Spending 2007-2011
  • Table 4-3: Pfizer’s Late Stage Product Pipeline
  • Figure 4-2: Pfizer’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-4: Merck’s* Total Company Revenue and R&D Spending 2007-2011
  • Table 4-5: Merck’s Late Stage Product Pipeline
  • Table 4-5 (continued): Merck’s Late Stage Product Pipeline
  • Figure 4-4: Merck’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-6: Novartis’ Total Company Revenue and R&D Spending 2007-2011
  • Table 4-7: Novartis’ Late Stage Product Pipeline
  • Figure 4-7: Novartis’ Late Stage Product Pipeline by Therapeutic Area
  • Table 4-8: Sanofi’s Total Company Revenue and R&D Spending 2007-2011
  • Table 4-9: Sanofi-Aventis’ Late Stage Product Pipeline
  • Figure 4-8: Sanofi Aventis’ Late Stage Product Pipeline by Therapeutic Area
  • Table 4-10: Roche’s Total Company Revenue and R&D Spending 2007-2011
  • Table 4-11: Roche’s Late Stage Product Pipeline
  • Figure 4-10: Roche’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-12: GlaxoSmithKline’s Total Company Revenue and R&D Spending 2007-2011
  • Table 4-13: GlaxoSmithKline’s Late Stage Product Pipeline
  • Figure 4-12: GlaxoSmithKline’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-14: AstraZeneca’s Total Company Revenue and R&D Spending 2007-2011
  • Table 4-15: AstraZeneca’s Late Stage Product Pipeline
  • Figure 4-14: AstraZeneca’ Late Stage Product Pipeline by Therapeutic Area
  • Table 4-16: Johnson & Johnson’s Total Company Revenue and R&D Spending 2007-2011
  • Table 4-17: Johnson & Johnson’s Late Stage Product Pipeline
  • Table 4-18: Eli Lilly’s Total Company Revenue and R&D Spending 2007-2011
  • Table 4-19: Eli Lilly’s Late Stage Product Pipeline
  • Figure 4-18: Eli Lilly & Co.’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-20: Abbott’s Total Company Revenue and R&D Spending 2007-2011
  • Table 4-21: Abbott’s Late Stage Product Pipeline
  • Figure 4-20: Abbott’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-22: Bristol-Myers Squibb’s Total Company Revenue and R&D Spending 2007-2011
  • Table 4-23: Bristol-Myers Squibb’s Late Stage Product Pipeline
  • Table 4-23: Bristol-Myers Squibb’s Late Stage Product Pipeline
  • Figure 4-22: Bristol-Myers’ Late Stage Product Pipeline by Therapeutic Area
  • Table 4-24: Takeda’s Total Company Revenue* and R&D Spending 2007-2011
  • Table 4-25: Takeda Pharmaceutical’s Late Stage Product Pipeline
  • Figure 4-24: Takeda Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-26: TEVA’s Total Company Revenue and R&D Spending 2007-2011
  • Table 4-27: TEVA’s Late Stage Product Pipeline
  • Figure 4-26: TEVA’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-28: Amgen’s Total Company Revenue and R&D Spending 2007-2011
  • Table 4-29: Amgen’s Late Stage Product Pipeline
  • Figure 4-28: Amgen’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-30: Boehringer Ingelheim’s Total Company Revenue and R&D Spending 2007-2011
  • Table 4-31: Boehringer Ingelheim’s Late Stage Product Pipeline
  • Figure 4-30: Boehringer Ingelheim’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-32: Bayer’s Total Company Revenue and R&D Spending 2007-2011
  • Table 4-33: Bayer’s Late Stage Product Pipeline
  • Figure 4-32: Bayers’ Late Stage Product Pipeline by Therapeutic Area
  • Table 4-34: Novo Nordisk’s Total Company Revenue and R&D Spending 2007-2011
  • Table 4-35: Novo Nordisk’s Late Stage Product Pipeline
  • Figure 4-34: Novo Nordisk’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-36: Astellas’ Total Company Revenue and R&D Spending 2007-2011
  • Table 4-37: Astellas’ Late Stage Product Pipeline
  • Figure 4-36: Astellas’ Late Stage Product Pipeline by Therapeutic Area
  • Table 4-38: Daiichi Sankyo’s Total Company Revenue and R&D Spending 2007-2011
  • Table 4-39: Daiichi Sankyo’s Late Stage Product Pipeline
  • Figure 4-38: Daiichi Sankyo’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-40: Otsuka Holding’s Total Company Revenue and R&D Spending 2007-2011
  • Table 4-41: Otsuka Pharmaceutical’s Late Stage Product Pipeline
  • Figure 4-40: Otsuka Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area

CHAPTER FIVE: COMPANIES OF INTEREST

  • Table 5-1: Top Biopharmaceutical Companies, 21-50 by 2011 SalesTable 5-2: Merck KGaA’s Late Stage Product Pipeline
  • Table 5-3: Gilead Sciences’ Late Stage Product Pipeline
  • Table 5-4: Eisai’s Late Stage Product Pipeline
  • Table 5-5: Celgene’s Late Stage Product Pipeline
  • Table 5-6: Mitsubishi Tanabe’s Late Stage Product Pipeline
  • Table 5-7: Allergan’s Late Stage Product Pipeline
  • Table 5-8: Forest Laboratories’ Late Stage Product Pipeline
  • Table 5-9: UCB Pharma’s Late Stage Product Pipeline
  • Table 5-10: Dainippon Sumitomo’s Late Stage Product Pipeline
  • Table 5-11: Shire’s Late Stage Product Pipeline
  • Table 5-12: Biogen Idec’s Late Stage Product Pipeline
  • Table 5-13: Hospira’s Late Stage Product Pipeline
  • Table 5-14: Lundbeck’s Late Stage Product Pipeline
  • Table 5-15: Kyowa Kirin’s Late Stage Product Pipeline
  • Table 5-16: Menarini’s Late Stage Product Pipeline
  • Table 5-17: Valeant’s Late Stage Product Pipeline
  • Table 5-18: Shionogi’s Late Stage Product Pipeline
  • Table 5-19: Actelion’s Late Stage Product Pipeline
  • Table 5-20: Ono Pharmaceutical’s Late Stage Product Pipeline
  • Table 5-21: Santen’s Late Stage Product Pipeline
  • Table 5-22: Taisho’s Late Stage Product Pipeline

CHAPTER SIX: MARKET FORECAST

  • Table 6-1: Top Biopharmaceutical Companies, 1-50 by 2011 SalesTable 6-1 (Continued): Top Pharmaceutical/Biopharmaceutical Companies, 1-50 by 2011 Sales
  • Table 6-2: Company Pipelines by Total Late Stage Development Projects
  • (Top 20 Companies by Revenues)
  • Figure 6-1: Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues)
  • Table 6-3: Global Pharmaceutical Market Value by Therapeutic Segment, 2005-2010
  • Figure 6-2: Global Pharmaceutical Market Value by Therapeutic Segment, 2005-2010
  • Table 6-4: Global Pharmaceutical Market Value by Therapeutic Segment, 2010 vs. 2011
  • Figure 6-3: Global Pharmaceutical Market Value by Therapeutic Segment, 2010 vs. 2011
  • Table 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016—based on late stage development projects evaluated
  • Figure 6-4: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016—based on late stage development projects evaluated
  • Figure 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016—Potential Impact from Late-Stage Development
  • Figure 6-6: Global Pharmaceutical Market Forecast by, 2016—Potential Impact from Late-Stage Development
  • Table 6-6: Top 5 Biotechnology Companies*, 2011 Sales
  • Table 6-7: Top 10 Biotechnology and Pharmaceutical Products, by 2011 Revenues
  • Figure 6-7: Top 10 Biotechnology and Pharmaceutical Products, by 2011 Revnues

 

Related products

The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 8th EditionEpigenetics: Applications for Pharmaceuticals and Diagnostics (Methylation,...